دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
A comprehensive update on valvular heart disease: from mechanisms to Guidelines
Filippo Crea
doi : 10.1093/eurheartj/ehac038
European Heart Journal, Volume 43, Issue 7, 14 February 2022, Pages 545–549
The promise and challenges of RNA-targeted therapeutics in preventive cardiology
Benoit J Arsenault
doi : 10.1093/eurheartj/ehab462
European Heart Journal, Volume 43, Issue 7, 14 February 2022, Pages 550–552
Mending damaged hearts
Mark Nicholls
doi : 10.1093/eurheartj/ehab470
European Heart Journal, Volume 43, Issue 7, 14 February 2022, Pages 553–555
Artificial intelligence: the pathway to the future of cardiovascular medicine
Thomas F Lüscher, Alexander Lyon, Ruth Amstein, Alan Maisel
doi : 10.1093/eurheartj/ehab472
European Heart Journal, Volume 43, Issue 7, 14 February 2022, Pages 556–558
PARADISE-MI suggests a limited role of intensified neuro-hormonal inhibition in the management of acute myocardial infarction with reduced ejection fraction
Giovanna Liuzzo, Massimo Volpe
doi : 10.1093/eurheartj/ehab861
European Heart Journal, Volume 43, Issue 7, 14 February 2022, Pages 559–560
2021 ESC/EACTS Guidelines for the management of valvular heart disease: Developed by the Task Force for the management of valvular heart disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)
Alec Vahanian, Friedhelm Beyersdorf, Fabien Praz, Milan Milojevic, Stephan Baldus, Johann Bauersachs, Davide Capodanno, Lenard Conradi, Michele De Bonis, Ruggero De Paulis,Victoria Delgado, Nick Freemantle, Martine Gilard, Kristina H Haugaa, Anders Jeppsson, Peter Jüni, Luc Pierard, Bernard D Prendergast, J Rafael Sádaba, Christophe Tribouilloy, Wojtek Wojakowski, ESC/EACTS Scientific Document Group
doi : 10.1093/eurheartj/ehab395
European Heart Journal, Volume 43, Issue 7, 14 February 2022, Pages 561–632
The year in cardiovascular medicine 2021: valvular heart disease
Helmut Baumgartner, Bernard Iung, David Messika-Zeitoun, Catherine M. Otto
doi : 10.1093/eurheartj/ehab885
European Heart Journal, Volume 43, Issue 7, 14 February 2022, Pages 633–640
Conservative, surgical, and percutaneous treatment for mitral regurgitation shortly after acute myocardial infarction
Dan Haberman, Rodrigo Estévez-Loureiro, Tomas Benito-Gonzalez, Paolo Denti, Dabit Arzamendi, Marianna Adamo, Xavier Freixa, Luis Nombela-Franco, Pedro Villablanca, Lian Krivoshei, Neil Fam, Konstantinos Spargias, Andrew Czarnecki, Isaac Pascual, Fabien Praz, Doron Sudarsky, Arthur Kerner, Vlasis Ninios, Marco Gennari, Ronen Beeri, Leor Perl, Yishay Wasserstrum, Haim Danenberg, Lion Poles, Jacob George, Berenice Caneiro-Queija, Salvatore Scianna, Igal Moaraf, Davide Schiavi, Claudia Scardino, Noé Corpataux, Julio Echarte-Morales, Michael Chrissoheris, EstefanÃa Fernández-Peregrina, Mattia Di Pasquale, Ander Regueiro, Carlos Vergara-Uzcategui, Andres Iñiguez-Romo, Felipe Fernández-Vázquez, Danny Dvir, Francesco Maisano, Maurizio Taramasso, Mony Shuvy
doi : 10.1093/eurheartj/ehab496
European Heart Journal, Volume 43, Issue 7, 14 February 2022, Pages 641–650
Severe mitral regurgitation (MR) following acute myocardial infarction (MI) is associated with high mortality rates and has inconclusive recommendations in clinical guidelines. We aimed to report the international experience of patients with secondary MR following acute MI and compare the outcomes of those treated conservatively, surgically, and percutaneously.
‘Primary’ percutaneous mitral valve repair in patients with acute myocardial infarction: is it ready for primetime?
David Messika-Zeitoun, Benjamin Hibbert, Vince Chan
doi : 10.1093/eurheartj/ehab540
European Heart Journal, Volume 43, Issue 7, 14 February 2022, Pages 651–653
TRI-SCORE: a new risk score for in-hospital mortality prediction after isolated tricuspid valve surgery
Julien Dreyfus, Etienne Audureau, Yohann Bohbot, Augustin Coisne, Yoan Lavie-Badie, Maxime Bouchery, Michele Flagiello, Baptiste Bazire, Florian Eggenspieler, Florence Viau, Elisabeth Riant, Yannick Mbaki, Damien Eyharts, Thomas Senage, Thomas Modine, Martin Nicol, Fabien Doguet, Virginia Nguyen, Thierry Le Tourneau, Christophe Tribouilloy, Erwan Donal, Jacques Tomasi, Gilbert Habib, Christine Selton-Suty, Richard Raffoul, Bernard Iung, Jean-François Obadia, David Messika-Zeitoun
doi : 10.1093/eurheartj/ehab679
European Heart Journal, Volume 43, Issue 7, 14 February 2022, Pages 654–662
Isolated tricuspid valve surgery (ITVS) is considered to be a high-risk procedure, but in-hospital mortality is markedly variable. This study sought to develop a dedicated risk score model to predict the outcome of patients after ITVS for severe tricuspid regurgitation (TR).
A new tool for the forgotten valve: a score to predict the risk of surgery
Antonio Colombo, Francesco Maisano
doi : 10.1093/eurheartj/ehab799
European Heart Journal, Volume 43, Issue 7, 14 February 2022, Pages 663–665
Trends in aortic valve replacement for aortic stenosis: a French nationwide study
Virginia Nguyen, Nadav Willner, Helene Eltchaninoff, Ian G Burwash, Morgane Michel, Eric Durand, Martine Gilard, Christel Dindorf, Bernard Iung, Alain Cribier, Alec Vahanian, Karine Chevreul, David Messika-Zeitoun
doi : 10.1093/eurheartj/ehab773
European Heart Journal, Volume 43, Issue 7, 14 February 2022, Pages 666–679
Transcatheter aortic valve replacement (TAVR) as an alternative to surgical aortic valve replacement (SAVR) has profoundly changed the management of patients with aortic valve stenosis (AS). Large unbiased nationwide data regarding TAVR implementation, impact on SAVR and their respective outcomes are scarce.
Aortic stenosis management in 2021: better teaming up than fighting between specialties
Helmut Baumgartner
doi : 10.1093/eurheartj/ehab778
European Heart Journal, Volume 43, Issue 7, 14 February 2022, Pages 680–682
Calcific aortic valve disease: from molecular and cellular mechanisms to medical therapy
Simon Kraler, Mark C Blaser, Elena Aikawa, Giovanni G Camici, Thomas F Lüscher
doi : 10.1093/eurheartj/ehab757
European Heart Journal, Volume 43, Issue 7, 14 February 2022, Pages 683–697
Calcific aortic valve disease (CAVD) is a highly prevalent condition that comprises a disease continuum, ranging from microscopic changes to profound fibro-calcific leaflet remodelling, culminating in aortic stenosis, heart failure, and ultimately premature death. Traditional risk factors, such as hypercholesterolaemia and (systolic) hypertension, are shared among atherosclerotic cardiovascular disease and CAVD, yet the molecular and cellular mechanisms differ markedly. Statin-induced low-density lipoprotein cholesterol lowering, a remedy highly effective for secondary prevention of atherosclerotic cardiovascular disease, consistently failed to impact CAVD progression or to improve patient outcomes. However, recently completed phase II trials provide hope that pharmaceutical tactics directed at other targets implicated in CAVD pathogenesis offer an avenue to alter the course of the disease non-invasively. Herein, we delineate key players of CAVD pathobiology, outline mechanisms that entail compromised endothelial barrier function, and promote lipid homing, immune-cell infiltration, and deranged phospho-calcium metabolism that collectively perpetuate a pro-inflammatory/pro-osteogenic milieu in which valvular interstitial cells increasingly adopt myofibro-/osteoblast-like properties, thereby fostering fibro-calcific leaflet remodelling and eventually resulting in left ventricular outflow obstruction. We provide a glimpse into the most promising targets on the horizon, including lipoprotein(a), mineral-binding matrix Gla protein, soluble guanylate cyclase, dipeptidyl peptidase-4 as well as candidates involved in regulating phospho-calcium metabolism and valvular angiotensin II synthesis and ultimately discuss their potential for a future therapy of this insidious disease.
Strengths and limitations of meta-analyses
Colin Berry
doi : 10.1093/eurheartj/ehab682
European Heart Journal, Volume 43, Issue 7, 14 February 2022, Page 698
Reporting data from meta-analysis: snapshot of a moving target
Yousif Ahmad, James P Howard, Mahesh V Madhavan, Sripal Bangalore, Gregg W Stone
doi : 10.1093/eurheartj/ehab681
European Heart Journal, Volume 43, Issue 7, 14 February 2022, Pages 699–700
Percutaneous closure of latent iatrogenic left ventricular pseudoaneurysm: role of patient-specific imaging planning
Ata Doost, Gerald Yong
doi : 10.1093/eurheartj/ehab545
European Heart Journal, Volume 43, Issue 7, 14 February 2022, Page 701
Mitral valvular nodules of acute rheumatic fever masquerading as intracardiac mass
Venkatakrishnan Ramakumar, Anunay Gupta, Kewal C Goswami, Priya Jagia, Sivasubramanian Ramakrishnan
doi : 10.1093/eurheartj/ehab638
European Heart Journal, Volume 43, Issue 7, 14 February 2022, Page 702
Responses to: The codex of science: honesty, precision, and truth—and its violations
doi : 10.1093/eurheartj/eht383
European Heart Journal, Volume 43, Issue 7, 14 February 2022, Page e1
Cognitive changes in prevalent and incident cardiovascular disease: a 12-year follow-up in the Maastricht Aging Study (MAAS)
Syenna H J Schievink, Martin P J van Boxtel, Kay Deckers, Robert J van Oostenbrugge, Frans R J Verhey, Sebastian Köhler
doi : 10.1093/eurheartj/ehx365
European Heart Journal, Volume 43, Issue 7, 14 February 2022, Pages e2–e9
Cardiovascular disease (CVD) has been suggested to accelerate cognitive decline and to be a risk factor for dementia, but still little is known about the cognitive course after a first cardiovascular event. Therefore, the present study aims to investigate the cognitive trajectories in both prevalent and incident CVD over a 12-year time period in the general population.
Is the amount of glow predicting the fire? Residual inflammatory risk after percutaneous coronary intervention
Alessandro Candreva, Christian M Matter
doi : 10.1093/eurheartj/ehy729
European Heart Journal, Volume 43, Issue 7, 14 February 2022, Pages e10–e13
Long-term exposure to high cholesterol accelerates cellular ageing
Christian M Werner, Ulrich Laufs
doi : 10.1093/eurheartj/ehy752
European Heart Journal, Volume 43, Issue 7, 14 February 2022, Pages e14–e16
Efficacy and safety of alirocumab and evolocumab: a systematic review and meta-analysis of randomized controlled trials
Paul Guedeney, Gennaro Giustino, Sabato Sorrentino, Bimmer E Claessen, Anton Camaj, Deborah N Kalkman, Birgit Vogel, Samantha Sartori, Salvatore De Rosa, Usman Baber, Ciro Indolfi, Gilles Montalescot, George D Dangas, Robert S Rosenson, Stuart J Pocock, Roxana Mehran
doi : 10.1093/eurheartj/ehz430
European Heart Journal, Volume 43, Issue 7, 14 February 2022, Pages e17–e25
The effect of low-density lipoprotein cholesterol-lowering therapy with alirocumab or evolocumab on individual clinical efficacy and safety endpoints remains unclear. We aimed to evaluate the efficacy and safety of alirocumab and evolocumab in patients with dyslipidaemia or atherosclerotic cardiovascular disease.
Genetics and causality in the educational attainment–coronary artery disease relationship
Aysu Okbay
doi : 10.1093/eurheartj/ehz457
European Heart Journal, Volume 43, Issue 7, 14 February 2022, Pages e26–e28
PCSK9 inhibitors: what we know, what we should have understood, and what is to come
Marc S Sabatine
doi : 10.1093/eurheartj/ehz514
European Heart Journal, Volume 43, Issue 7, 14 February 2022, Pages e29–e31
Unwrapped and uNCORked: PPAR-γ repression in atherosclerosis
Emiel P C Van der Vorst, Erik A L Biessen
doi : 10.1093/eurheartj/ehz770
European Heart Journal, Volume 43, Issue 7, 14 February 2022, Pages e32–e34
Iron deficiency in heart failure: why so frequent and which mechanisms?
Alain Cohen-Solal
doi : 10.1093/eurheartj/ehz874
European Heart Journal, Volume 43, Issue 7, 14 February 2022, Pages e35–e37
Gastrointestinal bleeding and the risk of colorectal cancer in anticoagulated patients with atrial fibrillation
Peter Vibe Rasmussen, Frederik Dalgaard, Gunnar Hilmar Gislason, Axel Brandes, Søren Paaske Johnsen, Erik Lerkevang Grove, Christian Torp-Pedersen, Lars Dybro, Louise Harboe, Anna-Marie Bloch Münster, Lasse Pedersen, Paul Blanche, Jannik Langtved Pallisgaard, Morten Lock Hansen
doi : 10.1093/eurheartj/ehz964
European Heart Journal, Volume 43, Issue 7, 14 February 2022, Pages e38–e44
Gastrointestinal bleeding (GI-bleeding) is frequent in patients with atrial fibrillation (AF) treated with oral anticoagulation (OAC) therapy. We sought to investigate to what extent lower GI-bleeding represents the unmasking of an occult colorectal cancer.
Cancer unmasked by bleeding during anticoagulant therapy: when a problem may become an opportunity
Felicita Andreotti, Aldo Pietro Maggioni
doi : 10.1093/eurheartj/ehaa164
European Heart Journal, Volume 43, Issue 7, 14 February 2022, Pages e45–e47
